Author Correction: Myeloid lineage enhancers drive oncogene synergy in CEBPA/CSF3R mutant acute myeloid leukemia.
Saved in:
| Title: | Author Correction: Myeloid lineage enhancers drive oncogene synergy in CEBPA/CSF3R mutant acute myeloid leukemia. |
|---|---|
| Authors: | Braun TP; Knight Cancer Institute, Oregon Health & Science University, Portland, OR, 97239, USA.; Division of Hematology and Medical Oncology, Oregon Health & Science University, Portland, OR, 97239, USA., Okhovat M; Knight Cardiovascular Institute, Oregon Health & Science University, Portland, OR, 97239, USA., Coblentz C; Knight Cancer Institute, Oregon Health & Science University, Portland, OR, 97239, USA.; Division of Hematology and Medical Oncology, Oregon Health & Science University, Portland, OR, 97239, USA., Carratt SA; Knight Cancer Institute, Oregon Health & Science University, Portland, OR, 97239, USA.; Division of Hematology and Medical Oncology, Oregon Health & Science University, Portland, OR, 97239, USA., Foley A; Knight Cancer Institute, Oregon Health & Science University, Portland, OR, 97239, USA.; Division of Hematology and Medical Oncology, Oregon Health & Science University, Portland, OR, 97239, USA., Schonrock Z; Knight Cancer Institute, Oregon Health & Science University, Portland, OR, 97239, USA.; Division of Hematology and Medical Oncology, Oregon Health & Science University, Portland, OR, 97239, USA., Curtiss BM; Knight Cancer Institute, Oregon Health & Science University, Portland, OR, 97239, USA.; Division of Hematology and Medical Oncology, Oregon Health & Science University, Portland, OR, 97239, USA., Nevonen K; Knight Cardiovascular Institute, Oregon Health & Science University, Portland, OR, 97239, USA., Davis B; Knight Cardiovascular Institute, Oregon Health & Science University, Portland, OR, 97239, USA., Garcia B; Knight Cancer Institute, Oregon Health & Science University, Portland, OR, 97239, USA.; Division of Hematology and Medical Oncology, Oregon Health & Science University, Portland, OR, 97239, USA., LaTocha D; Knight Cancer Institute, Oregon Health & Science University, Portland, OR, 97239, USA.; Division of Hematology and Medical Oncology, Oregon Health & Science University, Portland, OR, 97239, USA., Weeder BR; Program in Molecular and Cellular Biology, Oregon Health & Science University, Portland, OR, 97239, USA., Grzadkowski MR; Computational Biology Program, Oregon Health & Science University, Portland, OR, 97239, USA., Estabrook JC; Computational Biology Program, Oregon Health & Science University, Portland, OR, 97239, USA., Manning HG; Computational Biology Program, Oregon Health & Science University, Portland, OR, 97239, USA., Watanabe-Smith K; Knight Cancer Institute, Oregon Health & Science University, Portland, OR, 97239, USA.; Computational Biology Program, Oregon Health & Science University, Portland, OR, 97239, USA., Jeng S; Division of Bioinformatics and Computational Biology, Oregon Health & Science University, Portland, OR, 97239, USA., Smith JL; Clinical Research Division, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, Seattle, WA, 98109, USA., Leonti AR; Clinical Research Division, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, Seattle, WA, 98109, USA., Ries RE; Clinical Research Division, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, Seattle, WA, 98109, USA., McWeeney S; Knight Cancer Institute, Oregon Health & Science University, Portland, OR, 97239, USA.; Division of Bioinformatics and Computational Biology, Oregon Health & Science University, Portland, OR, 97239, USA., Di Genua C; MRC Molecular Haematology Unit, MRC Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Headley Way, Oxford, OX3 9DS, UK., Drissen R; MRC Molecular Haematology Unit, MRC Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Headley Way, Oxford, OX3 9DS, UK., Nerlov C; MRC Molecular Haematology Unit, MRC Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Headley Way, Oxford, OX3 9DS, UK., Meshinchi S; Clinical Research Division, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, Seattle, WA, 98109, USA.; Division of Pediatric Hematology/Oncology, University of Washington, Seattle, WA, 98195, USA., Carbone L; Knight Cardiovascular Institute, Oregon Health & Science University, Portland, OR, 97239, USA.; Division of Bioinformatics and Computational Biology, Oregon Health & Science University, Portland, OR, 97239, USA.; Department of Molecular and Medical Genetics, Oregon Health & Science University, Portland, OR, 97239, USA., Druker BJ; Knight Cancer Institute, Oregon Health & Science University, Portland, OR, 97239, USA.; Division of Hematology and Medical Oncology, Oregon Health & Science University, Portland, OR, 97239, USA.; Howard Hughes Medical Institute, Portland, OR, USA., Maxson JE; Knight Cancer Institute, Oregon Health & Science University, Portland, OR, 97239, USA. maxsonj@ohsu.edu.; Division of Hematology and Medical Oncology, Oregon Health & Science University, Portland, OR, 97239, USA. maxsonj@ohsu.edu. |
| Source: | Nature communications [Nat Commun] 2022 Jun 16; Vol. 13 (1), pp. 3471. Date of Electronic Publication: 2022 Jun 16. |
| Publication Type: | Published Erratum |
| Journal Info: | Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE; PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2041-1723 |
|---|---|
| DOI: | 10.1038/s41467-022-30987-0 |
